Chris Stevens – Chief Executive Officer & Executive Director – Coda Minerals (ASX:COD) is an advanced exploration company primed to unlock the value of the highly prospective Elizabeth Creek Copper Cobalt Project in South Australia’s world class mining jurisdiction, the Gawler Craton.
Copyright 2024 – Finance News Network
10 Oct 2023 - Harry Fisher - Project Manager - Benchmark’s prices and data empowers clients: from critical mineral contracts to EV battery supply chain investments and government policy.
10 June 2020 - Lepidico Limited (ASX:LPD) Managing Director, Joe Walsh provides an update on the company's plans to transition its Phase 1 Project to development following the recent completion of a Definitive Feasibility Study for the redevelopment of two mines in Namibia and a chemical conversion plant in Abu Dhabi that employs Lepidico’s proprietary process technologies.
11 Sep 2023 - QANTM Intellectual Property Limited (ASX:QIP) CEO and Managing Director Craig Dower discusses drivers of revenue, competitors and market share, and the company's ambitions to expand into Asia.
10 Oct 2023 - Dr Mike Jones - Managing Director - Impact Minerals (ASX:IPT) is an exploration company listed on the ASX in November 2006. The Company manages extensive tenement holdings (>4,000 km2) within Australia featuring significant potential for high-grade mineral deposits of gold, silver, lead, zinc, copper, nickel and PGM’s.
10 Jul 2023 - INOVIQ Limited (ASX:IIQ) CEO Dr Leearne Hinch discusses recent news, including excellent sensitivity and specificity results for the company's SubB2M breast cancer test.
09 Mar 2021 - Paragon Care Limited (ASX:PGC) CEO Phil Nicholl provides an update on the company's 1H21 results, discussing the increase in elective surgery and higher margin sales following COVID disruptions.
12 Feb 2020 - Mayur Resources Limited (ASX:MRL) Managing Director, Paul Mulder provides an update on the company's PNG projects, which span industrial minerals, power generation, coal, copper and gold.
24 Jun 2020 - Immutep (ASX:IMM) CEO, Marc Voigt provides an update on its clinical trials including metastatic breast cancer (MBC), its global leadership under Chief Scientist and Medical Officer, Professor Frederic Triebel, and the growing interest by big pharma in immuno-therapies.
